2024
Puzzolo, E., Fleeman, N., Lorenzetti, F., Rubinstein, F., Li, Y., Xing, R., . . . Pope, D. (2024). Estimated health effects from domestic use of gaseous fuels for cooking and heating in high-income, middle-income, and low-income countries: a systematic review and meta-analyses.. The Lancet. Respiratory medicine, 12(4), 281-293. doi:10.1016/s2213-2600(23)00427-7DOI: 10.1016/s2213-2600(23)00427-7
2023
Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.. PharmacoEconomics - open, 7(6), 1015. doi:10.1007/s41669-023-00462-7DOI: 10.1007/s41669-023-00462-7
Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - Open. doi:10.1007/s41669-023-00439-6DOI: 10.1007/s41669-023-00439-6
Bresnahan, R., Houten, R., Greenhalgh, J., Nevitt, S., Mahon, J., Beale, S., . . . Chaplin, M. (2023). Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. PharmacoEconomics - open. doi:10.1007/s41669-023-00408-zDOI: 10.1007/s41669-023-00408-z
Houten, R., Fleeman, N., Mahon, J., Chaplin, M., Edwards, K., Beale, S., . . . Palmieri, C. (2023). Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN. doi:10.1007/s41669-023-00405-2DOI: 10.1007/s41669-023-00405-2
Huang, Y., Fleeman, N., Doherty, A. J., Wilson, N., Boland, P., Clegg, A., . . . Marson, A. G. (2023). Service delivery, behavioural, and self‐management interventions for adults with epilepsy. The Cochrane database of systematic reviews, 2023(3).
Fleeman, N., Panebianco, M., Hill, R. A., Doherty, A. J., Nevitt, S. J., Boland, P., . . . Marson, A. G. (2023). Service delivery, behavioural, and self‐management interventions for children with epilepsy. The Cochrane database of systematic reviews, 2023(3).
2022
Nix, E., Fleeman, N., Lorenzetti, F., Lewis, J., Shen, G., Abebe, L., . . . Puzzolo, E. (2022). Health effects of liquid and gaseous fuels for household energy use: systematic evidence mapping. ENVIRONMENTAL RESEARCH LETTERS, 17(12). doi:10.1088/1748-9326/aca1d2DOI: 10.1088/1748-9326/aca1d2
Fleeman, N., Bradley, P. M., Panebianco, M., & Sharma, A. (2022). Care delivery and self-management strategies for children with epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (4). doi:10.1002/14651858.CD006245.pub5DOI: 10.1002/14651858.CD006245.pub5
2021
Pope, D., Johnson, M., Fleeman, N., Jagoe, K., Duarte, R., Maden, M., . . . Lewis, J. (2021). Are cleaner cooking solutions clean enough? A systematic review and meta-analysis of particulate and carbon monoxide concentrations and exposures. ENVIRONMENTAL RESEARCH LETTERS, 16(8). doi:10.1088/1748-9326/ac13ecDOI: 10.1088/1748-9326/ac13ec
Houten, R., Fleeman, N., Kotas, E., Boland, A., Lambe, T., & Duarte, R. (2021). A systematic review of health state utility values for thyroid cancer. QUALITY OF LIFE RESEARCH, 30(3), 675-702. doi:10.1007/s11136-020-02676-2DOI: 10.1007/s11136-020-02676-2
2020
Stainthorpe, A., Fleeman, N., Houten, R., Chaplin, M., Boland, A., Beale, S., . . . Syndikus, I. (2020). Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 4(4), 563-574. doi:10.1007/s41669-020-00203-0DOI: 10.1007/s41669-020-00203-0
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532] (Report)
Greenhalgh, J., Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., . . . Goodson, N. (2020). Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]: Ixekizumab for treating axial spondyloarthritis after NSAIDs[ID1532]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Fleeman, N., Houten, R., Bagust, A., Richardson, M., Beale, S., Boland, A., . . . Shenoy, A. (2020). Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 24(2), 1-+. doi:10.3310/hta24020DOI: 10.3310/hta24020
2019
Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., Dundar, Y., . . . Shenoy, A. (2019). A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC CANCER, 19(1). doi:10.1186/s12885-019-6369-7DOI: 10.1186/s12885-019-6369-7
Fleeman, N., Mahon, J., Nevitt, S., Duarte, R., Boland, A., Kotas, E., . . . Ahmad, S. (2019). Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 3(4), 453-461. doi:10.1007/s41669-019-0138-zDOI: 10.1007/s41669-019-0138-z
Fleeman, N., Bagust, A., Duarte, R., Richardson, M., Nevitt, S., Boland, A., . . . Thorp, N. (2019). Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 3(3), 293-302. doi:10.1007/s41669-018-0114-zDOI: 10.1007/s41669-018-0114-z
Fleeman, N., Dundar, Y., Shah, P. S., & Shaw, B. N. J. (2019). Heated Humidified High-Flow Nasal Cannula for Preterm Infants: An Updated Systematic Review and Meta-analysis. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 35(4), 298-306. doi:10.1017/S0266462319000424DOI: 10.1017/s0266462319000424
2018
Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (Report)
Fleeman, N., Mahon, J., Chaplin, M., Boland, A., Beale, S., De Sousa Rego Vieira Duarte, R., . . . Green, J. (2018). Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer: Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non- small-cell lung cancer (17/141/08). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta621/documents/committee-papers
Fleeman, N., Stainthorpe, A., Houten, R., Chaplin, M., Boland, A., Beale, S., . . . Isabel, S. (2018). Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma (17/56/12): Brentuximab vedotin for treating relapsed or refractory CD30- positive cutaneous T-cell lymphoma (17/56/12). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta577/documents/committee-papers
Fleeman, N., & Bradley, P. M. (2018). Care delivery and self-management strategies for children with epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (3). doi:10.1002/14651858.C.D006245.pub4DOI: 10.1002/14651858.C.D006245.pub4
Fleeman, N., & Bradley, P. M. (2018). Care delivery and self-management strategies for children with epilepsy.. The Cochrane database of systematic reviews, 3, CD006245. doi:10.1002/14651858.cd006245.pub4DOI: 10.1002/14651858.cd006245.pub4
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal (Journal article)
Fleeman, N., Abdulla, A., Bagust, A., Beale, S., Richardson, M., Stainthorpe, A., . . . Palmer, D. (2018). Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 36(3), 289-299. doi:10.1007/s40273-017-0592-3DOI: 10.1007/s40273-017-0592-3
2017
Martin, A., Downing, J., Maden, M., Fleeman, N., Alfirevic, A., Haycox, A., & Pirmohamed, M. (2017). An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review. PHARMACOGENOMICS, 18(16), 1541-1550. doi:10.2217/pgs-2017-0076DOI: 10.2217/pgs-2017-0076
Fleeman, N., Bagust, A., Duarte, R., Chaplin, M., Nevitt, S., Boland, A., . . . Thorp, N. (n.d.). Eribulin for treating locally advanced or metastatic breast cancer after one prior chemotherapy regimen (ID1072). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta515/documents/committee-papers
Fleeman, N., Bagust, A., Boland, A., Beale, S., Richardson, M., Krishan, A., . . . Payne, M. (2017). Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 35(10), 1035-1046. doi:10.1007/s40273-017-0504-6DOI: 10.1007/s40273-017-0504-6
Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer (Report)
Greenhalgh, J. (n.d.). Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer (ID1059). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta535/documents/committee-papers
2016
Greenhalgh, J. (n.d.). Palbociclib for treating metastatic, hormone receptor-positive, HER2-negative breast cancer (ID915). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta495/documents/committee-papers-2
Greenhalgh, J. (n.d.). Eribulin for locally advanced or metastatic breast cancer (ID964). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10030/documents/committee-papers
Greenhalgh, J. (n.d.). Nanoliposomal irinotecan for treating pancreatic cancer after prior treatment with gemcitabine (ID778). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta440/documents/committee-papers-2
Fleeman, N., Mahon, J., Bates, V., Dickson, R., Dundar, Y., Dwan, K., . . . Shaw, B. N. J. (2016). The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 20(30), 1-67. doi:10.3310/hta20300DOI: 10.3310/hta20300
Bradley, P. M., Lindsay, B., & Fleeman, N. (2016). Care delivery and self management strategies for adults with epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (2). doi:10.1002/14651858.CD006244.pub3DOI: 10.1002/14651858.CD006244.pub3
Fleeman, N., Bagust, A., Boland, A., Beale, S., Chaplin, M., Krishan, A., . . . Payne, M. (2016). Talimogene laherparepvec for treating metastatic melanoma: Talimogene laherparepvec for treating metastatic melanoma (14/206/04). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-tag509/documents/committee-papers-2
2015
Fleeman, N., Bradley, P. M., & Lindsay, B. (2015). Care delivery and self management strategies for children with epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (12). doi:10.1002/14651858.CD006245.pub3DOI: 10.1002/14651858.CD006245.pub3
Nicholson, A., Mahon, J., Boland, A., Beale, S., Dwan, K., Fleeman, N., . . . Dundar, Y. (2015). The clinical effectiveness and cost-effectiveness of the PROGENSA (R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technology Assessment, 19(87), 1-+. doi:10.3310/hta19870DOI: 10.3310/hta19870
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dickson, R., Dwan, K., . . . Banks, L. (2015). Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. PHARMACOECONOMICS, 33(9), 893-904. doi:10.1007/s40273-015-0276-9DOI: 10.1007/s40273-015-0276-9
Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab (Report)
Fleeman, N., Bagust, A., Chaplin, M., Krishan, A., Boland, A., Beale, S., . . . Payne, M. (2015). Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab: Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab (14/177/07). NICE Website. Retrieved from https://www.nice.org.uk/
Ciclosporin for treating dry eye disease (Report)
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dwan, K., Kotas, E., . . . Ahmad, S. (2015). Ciclosporin for treating dry eye disease: Ciclosporin for treating dry eye disease (13/166/01). NICE Website. Retrieved from https://www.nice.org.uk/
Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Oyee, J., Trevor, N., Beale, S., . . . O'Reilly, S. (2015). Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal. PharmacoEconomics, 33(2), 137-148. doi:10.1007/s40273-014-0214-2DOI: 10.1007/s40273-014-0214-2
Shabaruddin, F. H., Fleeman, N. D., & Payne, K. (2015). Economic evaluations of personalized medicine: existing challenges and current developments. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 8, 115-126. doi:10.2147/PGPM.S35063DOI: 10.2147/PGPM.S35063
Protogerou, C., Fleernan, N., Dwan, K., Richardson, M., Dundar, Y., & Hagger, M. S. (2015). Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis. BEHAVIOUR RESEARCH AND THERAPY, 73, 151-164. doi:10.1016/j.brat.2015.08.004DOI: 10.1016/j.brat.2015.08.004
Fleeman, N., Bagust, A., Beale, S., Dwan, K., Dickson, R., Proudlove, C., & Dundar, Y. (2015). Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer. PHARMACOECONOMICS, 33(1), 13-23. doi:10.1007/s40273-014-0206-2DOI: 10.1007/s40273-014-0206-2
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Dwan, K., Beale, S., Fleeman, N., . . . Fisher, M. (2015). Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 19(29), 1-+. doi:10.3310/hta19290DOI: 10.3310/hta19290
2014
Deferasirox for managing iron overload in people with myelodysplastic syndrome (Journal article)
Meerpohl, J. J., Schell, L. K., Ruecker, G., Fleeman, N., Motschall, E., Niemeyer, C. M., & Bassler, D. (2014). Deferasirox for managing iron overload in people with myelodysplastic syndrome. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (10). doi:10.1002/14651858.CD007461.pub3DOI: 10.1002/14651858.CD007461.pub3
Fleeman, N., Bagust, A., Boland, A., Dwan, K., Chaplin, M., Beale, S., . . . Greystoke, A. (2014). Nintedanib for previously treated locally advanced or metastatic non small cell lung cancer: Nintedanib for previously treated locally advanced or metastatic non-small cell lung cancer (13/106/01). NICE Website. Retrieved from https://www.nice.org.uk/
Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma (Report)
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dickson, R., Dwan, K., . . . Banks, L. (2014). Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma: Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma (12/54). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta321/history
Deferasirox for managing transfusional iron overload in people with sickle cell disease (Journal article)
Meerpohl, J. J., Schell, L. K., Ruecker, G., Motschall, E., Fleeman, N., Niemeyer, C. M., & Bassler, D. (2014). Deferasirox for managing transfusional iron overload in people with sickle cell disease. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (5), 1-77. doi:10.1002/14651858.CD007477.pub3DOI: 10.1002/14651858.CD007477.pub3
Allopurinol for the treatment of chronic kidney disease: a systematic review (Journal article)
Fleeman, N., Pilkington, G., Dundar, Y., Dwan, K., Boland, A., Dickson, R., . . . Pyatt, J. (2014). Allopurinol for the treatment of chronic kidney disease: a systematic review. HEALTH TECHNOLOGY ASSESSMENT, 18(40), 1-+. doi:10.3310/hta18400DOI: 10.3310/hta18400
EFFICACY OF PSYCHOLOGICAL INTERVENTIONS TO REDUCE DISTRESS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES: A META-ANALYSIS (Conference Paper)
Protogerou, C., Fleeman, N. F., Dwain, K. D., Richardson, M. R., Dundar, Y. D., & Dickson, R. D. (2014). EFFICACY OF PSYCHOLOGICAL INTERVENTIONS TO REDUCE DISTRESS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES: A META-ANALYSIS. In INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE Vol. 21 (pp. S63). Retrieved from https://www.webofscience.com/
2013
Are health technology assessments of pharmacogenetic tests feasible? A case study of <i>CYP2D6</i> testing in the treatment of breast cancer with tamoxifen (Journal article)
Fleeman, N., Payne, K., Newman, W. G., Howell, S. J., Boland, A., Oyee, J., . . . Dickson, R. (2013). Are health technology assessments of pharmacogenetic tests feasible? A case study of <i>CYP2D6</i> testing in the treatment of breast cancer with tamoxifen. PERSONALIZED MEDICINE, 10(6), 601-611. doi:10.2217/pme.13.60DOI: 10.2217/pme.13.60
2012
Deferasirox for managing iron overload in people with thalassaemia (Journal article)
Meerpohl, J. J., Antes, G., Ruecker, G., Fleeman, N., Motschall, E., Niemeyer, C. M., & Bassler, D. (2012). Deferasirox for managing iron overload in people with thalassaemia. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (2). doi:10.1002/14651858.CD007476.pub2DOI: 10.1002/14651858.CD007476.pub2
2011
The clinical effectiveness and cost-effectiveness of genotyping for <i>CYP2D6</i> for the management of women with breast cancer treated with tamoxifen: a systematic review (Journal article)
Fleeman, N., Martin Saborido, C., Payne, K., Boland, A., Dickson, R., Dundar, Y., . . . Walley, T. (2011). The clinical effectiveness and cost-effectiveness of genotyping for <i>CYP2D6</i> for the management of women with breast cancer treated with tamoxifen: a systematic review. HEALTH TECHNOLOGY ASSESSMENT, 15(33), XIII-+. doi:10.3310/hta15330DOI: 10.3310/hta15330
Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE (Journal article)
Bagust, A., Greenhalgh, J., Boland, A., Fleeman, N., McLeod, C., Dickson, R., . . . Shaw, R. (2011). Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE. PharmacoEconomics Italian Research Articles, 13(2), 101-110. doi:10.1007/bf03320687DOI: 10.1007/bf03320687
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses (Journal article)
Fleeman, N., Dundar, Y., Dickson, R., Jorgensen, A., Pushpakom, S., McLeod, C., . . . Walley, T. (2011). Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. PHARMACOGENOMICS JOURNAL, 11(1), 1-14. doi:10.1038/tpj.2010.73DOI: 10.1038/tpj.2010.73
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis (Journal article)
Fleeman, N., Bagust, A., Boland, A., Dickson, R., Dundar, Y., Moonan, M., . . . Thorp, N. (2011). Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 15(42), 1-+. doi:10.3310/hta15420DOI: 10.3310/hta15420
2010
Deferasirox for managing iron overload in people with myelodysplastic syndrome (Journal article)
Meerpohl, J. J., Antes, G., Ruecker, G., Fleeman, N., Motschall, E., Niemeyer, C. M., & Bassler, D. (2010). Deferasirox for managing iron overload in people with myelodysplastic syndrome. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (11). doi:10.1002/14651858.CD007461.pub2DOI: 10.1002/14651858.CD007461.pub2
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Greenhalgh, J., McLeod, C., Bagust, A., Boland, A., Fleeman, N., Dundar, Y., . . . Pearson, M. (n.d.). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment, 14(Suppl 2), 33-39. doi:10.3310/hta14suppl2-05DOI: 10.3310/hta14suppl2-05
Deferasirox for managing transfusional iron overload in people with sickle cell disease (Journal article)
Meerpohl, J. J., Antes, G., Ruecker, G., Fleeman, N., Niemeyer, C., & Bassler, D. (2010). Deferasirox for managing transfusional iron overload in people with sickle cell disease. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (8). doi:10.1002/14651858.CD007477.pub2DOI: 10.1002/14651858.CD007477.pub2
Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck A NICE Single Technology Appraisal (Journal article)
Bagust, A., Greenhalgh, J., Boland, A., Fleeman, N., McLeod, C., Dickson, R., . . . Shaw, R. (2010). Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck A NICE Single Technology Appraisal. PHARMACOECONOMICS, 28(6), 439-448. doi:10.2165/11532220-000000000-00000DOI: 10.2165/11532220-000000000-00000
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Fleeman, N., Bagust, A., McLeod, C., Greenhalgh, J., Boland, A., Dundar, Y., . . . Pearson, M. (n.d.). Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment, 14(Suppl 1), 47-53. doi:10.3310/hta14suppl1-07DOI: 10.3310/hta14suppl1-07
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (n.d.). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Health Technology Assessment, 14(Suppl 1), 31-38. doi:10.3310/hta14suppl1-05DOI: 10.3310/hta14suppl1-05
Abatacept for the treatment of rheumatoid arthritis (Journal article)
Hockenhull, J., Boland, A., Bagust, A., Dundar, Y., Fleeman, N., Kennedy, T., . . . Dickson, R. (2010). Abatacept for the treatment of rheumatoid arthritis. Health Technology Assessment. Retrieved from http://www.hta.ac.uk/project/1648.asp
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Fleeman, N., Bagust, A., McLeod, C., Greenhalgh, J., Boland, A., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 47-53. doi:10.3310/hta14suppl1/07DOI: 10.3310/hta14suppl1/07
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Greenhalgh, J., McLeod, C., Bagust, A., Boland, A., Fleeman, N., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 33-39. doi:10.3310/hta14suppl2/05DOI: 10.3310/hta14suppl2/05
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (2010). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. HEALTH TECHNOLOGY ASSESSMENT, 14, 31-38. doi:10.3310/hta14suppl1/05DOI: 10.3310/hta14suppl1/05
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (n.d.). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Health Technology Assessment, 14(Suppl 1). doi:10.3310/hta14suppl1/05DOI: 10.3310/hta14suppl1/05
The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation (Journal article)
Fleeman, N., McLeod, C., Bagust, A., Beale, S., Boland, A., Dundar, Y., . . . Dickson, R. (2010). The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 14(3), 1-+. doi:10.3310/hta14030DOI: 10.3310/hta14030
2009
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Fleeman, N., McLeod, C., Dundar, Y., . . . Shaw, R. (n.d.). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technology Assessment, 13(Suppl 3), 49-54. doi:10.3310/hta13suppl3-08DOI: 10.3310/hta13suppl3-08
Rituximab for the treatment of rheumatoid arthritis (Journal article)
Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., . . . Dickson, R. (n.d.). Rituximab for the treatment of rheumatoid arthritis. Health Technology Assessment, 13(Suppl 2), 23-29. doi:10.3310/hta13suppl2-04DOI: 10.3310/hta13suppl2-04
Providing patients with information on pharmacogenetic testing (Journal article)
Fleeman, N., & Dickson, R. (2009). Providing patients with information on pharmacogenetic testing. Nursing Standard, 23(21), 46-51. doi:10.7748/ns.23.21.46.s51DOI: 10.7748/ns.23.21.46.s51
Providing patients with information on pharmacogenetic testing. (Journal article)
Fleeman, N., & Dickson, R. (2009). Providing patients with information on pharmacogenetic testing.. Nursing standard (Royal College of Nursing (Great Britain) : 1987), 23(21), 46-48. doi:10.7748/ns2009.01.23.21.46.c6768DOI: 10.7748/ns2009.01.23.21.46.c6768
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Fleeman, N., McLeod, C., Dundar, Y., . . . Shaw, R. (2009). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. HEALTH TECHNOLOGY ASSESSMENT, 13, 49-54. doi:10.3310/hta13suppl3/08DOI: 10.3310/hta13suppl3/08
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation (Journal article)
McLeod, C., Fleeman, N., Kirkham, J., Bagust, A., Boland, A., Chu, P., . . . Walley, T. (2009). Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 13(1), 1-+. doi:10.3310/hta13010DOI: 10.3310/hta13010
Rituximab for the treatment of rheumatoid arthritis (Journal article)
Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., . . . Dickson, R. (2009). Rituximab for the treatment of rheumatoid arthritis. HEALTH TECHNOLOGY ASSESSMENT, 13, 23-29. doi:10.3310/hta13suppl2/04DOI: 10.3310/hta13suppl2/04
2008
Deferasirox for managing iron overload in patients with myelodysplastic syndrome (Journal article)
Meerpohl, J. J., Antes, G., Rücker, G., McLeod, C., Fleeman, N., Niemeyer, C., & Bassler, D. (n.d.). Deferasirox for managing iron overload in patients with myelodysplastic syndrome. doi:10.1002/14651858.cd007461DOI: 10.1002/14651858.cd007461
Deferasirox for managing iron overload in people with thalassaemia (Journal article)
Meerpohl, J. J., Antes, G., Rücker, G., McLeod, C., Fleeman, N., Niemeyer, C. M., & Bassler, D. (n.d.). Deferasirox for managing iron overload in people with thalassaemia. doi:10.1002/14651858.cd007476DOI: 10.1002/14651858.cd007476
Deferasirox for managing transfusional iron overload in people with sickle cell disease (Journal article)
Meerpohl, J. J., Antes, G., Rücker, G., McLeod, C., Fleeman, N., Niemeyer, C., & Bassler, D. (n.d.). Deferasirox for managing transfusional iron overload in people with sickle cell disease. doi:10.1002/14651858.cd007477DOI: 10.1002/14651858.cd007477
So many filters, so little time: the development of a search filter appraisal checklist (Journal article)
Glanville, J., Bayliss, S., Booth, A., Dundar, Y., Fernandes, H., Fleeman, N. D., . . . Welch, K. (2008). So many filters, so little time: the development of a search filter appraisal checklist. JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION, 96(4), 356-361. doi:10.3163/1536-5050.96.4.011DOI: 10.3163/1536-5050.96.4.011
2000
A prospective health impact assessment of the Merseyside Integrated Transport Strategy (MerITS) (Journal article)
Fleeman, N., & Scott-Samuel, A. (2000). A prospective health impact assessment of the Merseyside Integrated Transport Strategy (MerITS). JOURNAL OF PUBLIC HEALTH MEDICINE, 22(3), 268-274. Retrieved from https://www.webofscience.com/
1997
Alcohol home detoxification: a literature review. (Journal article)
Fleeman, N. D. (1997). Alcohol home detoxification: a literature review.. Alcohol and alcoholism (Oxford, Oxfordshire), 32(6), 649-656. doi:10.1093/oxfordjournals.alcalc.a008315DOI: 10.1093/oxfordjournals.alcalc.a008315
Undated
Puzzolo, E., Fleeman, N., Lorenzetti, F., Rubinstein, F., Li, Y., Xing, R., . . . Pope, D. (n.d.). Health Effects from Domestic Use of Gaseous and Liquid Fuels for Cooking and Heating in High, Middle and Low-Income Countries: A Systematic Review and Meta-Analysis.